Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6805903 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2MEN1KMT2AHDAC3HDAC4 | |
| SCHEMBL22111278 | 0.87 | SMN1; SMN2 (0.40) | SMN1; SMN2MEN1KMT2AHDAC3HDAC4 | |
| SCHEMBL6670756 | 0.84 | KIF11 (0.46) | SMN1; SMN2MEN1KMT2AHDAC8HDAC6 | |
| SCHEMBL6670753 | 0.84 | KIF11 (0.46) | SMN1; SMN2MEN1KMT2AHDAC8HDAC6 | |
| SCHEMBL6805400 | 0.83 | KIF11 (0.42) | ALDH1A1CA1CA2CA9LMNA | |
| SCHEMBL6805401 | 0.83 | KIF11 (0.42) | ALDH1A1CA1CA2CA9LMNA | |
| SCHEMBL88835 | 0.82 | HDAC3 (0.44) | KMT2AHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL5981504 | 0.82 | HDAC3 (0.44) | KMT2AHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6805659 | 0.82 | SMN1; SMN2 (0.47) | SMN1; SMN2MEN1KMT2AALDH1A1RAB9A | |
| SCHEMBL6806879 | 0.82 | KCNN4 (0.45) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | SUTRO BIOPHARMA, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20160257709-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160257709-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. | 2016-09-08 | — | — | US | disclosed |
| WO-2016123582-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
| US-20040121965-A1 | Method of treating resistant tumors | WYETH HOLDINGS CORPORATION (US) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257709-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | CYP17A1, HSD17B7, SHBG | SMN1; SMN2 2005/4885MEN1 676/4885KMT2A 2712/4885 |
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | FCGR1A, FCGR2A, FCGRT | SMN1; SMN2 3797/4885MEN1 4427/4885KMT2A 2495/4885 |
| US-20040121965-A1 | Method of treating resistant tumors | SLC11A2, VHL, REN | SMN1; SMN2 1481/4885MEN1 40/4885KMT2A 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.